Mybacs has successfully completed a financing round. According to a press release, existing investors such as the German venture capital fund Global Founders Capital as well as new investors such as Joyance Partners in San Francisco participated in the round. The amount raised has not been disclosed.
Mybacs develops synbiotic dietary supplements with formulations of specifically selected bacteria cultures, prebiotics as well as minerals and vitamins that are tailored to the individual needs of its customers. In 2018, mybacs launched its travel product Travelbacs, a regionally tailored bacterial composition to help prepare the digestion for specific travel regions. In 2019, the startup expanded its product portfolio with Dailybacs, a synbiotic for daily use that is available on a subscription basis.
The startup will use the new capital to develop new products that will respond even more specifically to the individual needs of its customers, said Carl-Philipp von Polheim, founder and co-CEO of mybacs.
“Accordingly, we will expand our team to include specialists in the fields of technology and data, and will continue to drive forward the personalization of our products with the help of a platform for synbiotic and intelligent data analysis,” von Polheim said in the press release.
Mybacs has offices in Zug and Munich.
Related news
Meet with an expansion expert
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line.